The CD2AP Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human hepatocellular carcinoma cell line Huh-7, engineered to disrupt the CD2AP gene. This knockout model provides a consistent loss-of-function system for investigating CD2AP’s roles without requiring clonal isolation, capturing population-level variation while maintaining robust target-gene disruption. The polyclonal format supports reproducible studies of CD2AP-dependent phenotypes across multiple experimental assays and batch preparations.
The Huh-7 cell line originates from a Japanese male hepatocellular carcinoma and serves as a widely used model for hepatocyte function and liver cancer research. These epithelial cells retain hepatocyte-like properties, including albumin secretion and drug-metabolizing enzyme activity, making them suitable for studying liver-specific processes. Huh-7 cells are instrumental in exploring hepatocellular carcinoma biology, therapeutic response, and hepatocarcinogenesis, providing a relevant background for dissecting CD2AP’s role in hepatic pathophysiology.
CD2AP is an adaptor protein that orchestrates actin cytoskeleton dynamics by bridging membrane receptors to the actin remodeling machinery. It is activated by T cell receptor stimulation, epidermal growth factor (EGF) engagement, CD2 ligation, and integrin signaling, and functions downstream of kinases such as LCK and ZAP-70 in immune contexts or EGFR-PI3K-AKT in carcinoma cells. CD2AP directly interacts with cortactin, nephrin, p130Cas, Rab4, and the tight junction proteins ZO-1 and occludin, linking them to the WAVE complex and Arp2/3 to drive actin polymerization. In Huh-7 cells, CD2AP participates in receptor tyrosine kinase signaling, tight junction assembly, and cell adhesion. Gene disruption of CD2AP destabilizes actin networks, impairs tight junction integrity, and alters endocytic trafficking, thereby perturbing downstream pathways such as Rac1-mediated cytoskeletal reorganization.
In the context of hepatocellular carcinoma, CD2AP’s regulation of actin dynamics and cell adhesion is particularly relevant to tumor progression, including migration, invasion, and metastasis. The CD2AP Knockout Huh-7 Polyclonal Cells enable dissection of how CD2AP contributes to hepatocyte polarity, junctional stability, and epithelial-to-mesenchymal transition programs. Because CD2AP is also implicated in focal segmental glomerulosclerosis through its interaction with nephrin and in Alzheimer’s disease via cytoskeletal disruption, this model extends to studying shared molecular mechanisms across tissue pathologies. By ablating CD2AP in a liver cancer background, researchers can evaluate its context-specific functions in actin-dependent processes and signal integration.
This knockout cell population is suited for a broad array of functional assays, including western blotting to assess CD2AP and actin regulatory proteins, immunofluorescence microscopy to visualize F-actin and tight junction markers like ZO-1, wound healing migration assays, Transwell invasion studies, and proliferation analyses. Additionally, these cells can be employed in xenograft tumor growth assays to evaluate the impact of CD2AP loss on tumorigenicity and metastatic potential in vivo. Drug response studies in hepatocellular carcinoma can leverage this model to identify CD2AP-dependent sensitivities to kinase inhibitors or cytoskeletal drugs. For further details or to discuss custom applications, researchers are encouraged to contact Ascent Research.
